SNSE earnings analysis
What we found in SNSE's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Sensei Biotherapeutics is focusing on developing cancer therapies using multi-node inhibition strategies following their acquisition of Faeth Therapeutics, which introduced the promising lead asset PIKTOR targeting critical cancer pathways. Financially, the company has not generated revenue and has posted significant losses, with EPS reported at -131.45 in Q1 2026 and operational challenges evident in substantial yearly net losses attributed mainly to R&D expenses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strategic Acquisition Enhances Pipeline
- The acquisition of Faeth Therapeutics enables access to the promising lead asset PIKTOR, a multi-node inhibitor targeting the PI3K/AKT/mTOR pathway.
- Ongoing Clinical Trials for PIKTOR
- Current trials for PIKTOR in advanced endometrial cancer and HR+/HER2- breast cancer are crucial steps with data expected in 2026 and 2027.
- Potential Market Opportunity
- The addressable market for the targeted indications is estimated at $6 billion in the U.S., primarily from HR+/HER2- breast cancer and endometrial cancer.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Significant Operational Losses
- Sensei reported a net loss of approximately $170.2 million in Q1 2026, primarily from R&D expenses, raising liquidity concerns.
- Zero Revenue Generation
- The company has continued to report zero revenue, indicating severe operational difficulties or feasibility issues.
- High Financial Burden from Acquisition
- The acquisition of Faeth, while strategic, has added substantial debts and liabilities which could strain future financial performance.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-3.74
What they said about what is next.
No forward guidance provided; additional metrics likely discussed in earnings calls.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Sensei Biotherapeutics reported significant losses in Q1 2026, reflecting a net loss of $170.2 million, primarily from the acquisition of Faeth Therapeutics, which added $133 million in acquired in-process R&D expenses.…
- 10-K · March 30, 2026
- Sensei completed the acquisition of Faeth Therapeutics on February 17, 2026 and received $200.0 million in gross proceeds from a 2026 private placement to advance Faeth’s lead asset, PIKTOR. PIKTOR is now the company's…
- 10-Q · November 14, 2025
- Sensei reported a Q3 2025 net loss per share of $(3.62), an improvement from $(5.77) in Q3 2024 and from $(3.91) in Q2 2025. Operating expenses declined to $4,851,000 in Q3 2025 from $7,823,000 in Q3 2024, but the…
- 10-K · March 28, 2025
- Sensei Biotherapeutics positions itself as a tumor-microenvironment–focused biotech developing pH-selective antibodies from its TMAb platform, with solnerstotug (SNS-101) as the lead asset. The company reported…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SNSE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever